Navigation Links
Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2010 Financial Results
Date:2/28/2011

" for purposes of the safe harbor provisions of The Private Securities Litigation Reform Act of 1995, including but not limited to the statements regarding the company's future business and financial performance. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words "expect," "plans," "anticipates," "will," and similar expressions are also intended to identify forward-looking statements, as are expressed or implied statements with respect to the company's potential pipeline candidates, including any expressed or implied statements regarding the efficacy and safety of our drug candidates, the likelihood and success of any future clinical trials involving our drug candidates. Actual results may differ materially from those indicated by such forward-looking statements as a result of risks and uncertainties, including but not limited to the following: there can be no guarantees that the company will advance any clinical product candidate or other component of its potential pipeline to the clinic, to the regulatory process or to commercialization; management's expectations could be affected by unexpected regulatory actions or delays; uncertainties relating to, or unsuccessful results of, clinical trials, including additional data relating to the ongoing clinical trials evaluating its product candidates; the company's ability to obtain additional funding required to conduct its research, development and commercialization activities; the company's dependence on its collaborations with Novartis Pharma AG and GlaxoSmithKline/ViiV Healthcare; changes in the company's business plan or objectives; the ability of the company to attract and retain qualified personnel; competition in general; and the company's ability to obtain, maintain and enforce patent and other intellectual property protection for its product candidates and its discoveries. Such forward-l
'/>"/>
SOURCE Idenix Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Idenix Pharmaceuticals to Hold an Investor/Analyst Day Event on October 30, 2010
2. Idenix Pharmaceuticals to Present at an Upcoming Investor Conference
3. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
4. Idenix Retains Worldwide Rights to Develop and Commercialize IDX184 for the Treatment of HCV
5. Idenix Announces Data Presentations at the 60th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
6. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
7. Idenix Pharmaceuticals Prices Underwritten Offering of Common Stock
8. Idenix Pharmaceuticals Reports Second Quarter and Six Month 2009 Financial Results
9. Idenix to Host Conference Call Discussing Second Quarter 2009 Financial Results
10. Idenix Pharmaceuticals to Present at The Deutsche Bank 2009 Health Care Conference
11. Idenix Pharmaceuticals Reports First Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... 2014 LayerBio is an MIT spin-off ... care. The National Eye Institute (NEI) at the National ... I SBIR grant to develop a drug-eluting intraocular lens ... common cause of vision loss in people over age ... to Dr. Ken Mandell, LayerBio’s Founder and CEO, "There ...
(Date:12/19/2014)... iLab Solutions, the global leader in core ... as the new Director of Institutional Implementations and Sarah ... two new leadership positions were created to support iLab’s ... iLab continues to meet the needs of its growing ... has been deployed at over 450 core facilities across ...
(Date:12/19/2014)... With only 2 weeks left of 2014, ... Biohit products . The product specials include Buy 1 ... Trade-in Program, and free pipette tips. , Sartorius mLINE ... world. They are ideal for lab technicians performing long ... ,     Full volume range of 0.1 uL to 10 ...
(Date:12/19/2014)... , Dec. 18, 2014   ISN has ... Safety Performance Indicators publication series. With data ... activity reported in 2013 within its online contractor management ... safety key performance indicator (KPI) statistics. ... U.S. publication is available in two industry ...
Breaking Biology Technology:LayerBio Awarded NIH Grant to Develop a Drug Delivery Device for Cataract Surgery 2iLab Solutions Announces Two New Leadership Positions to Meet the Needs of Its Growing Customer Base 2Major Pipette Distributor Pipette.com Announces Sartorius Year End Specials 2ISN Releases Third Edition of US Contractor Health & Safety Performance Indicators Publication Series 2ISN Releases Third Edition of US Contractor Health & Safety Performance Indicators Publication Series 3
... have unlocked the physics of the perfect pizza toss ... of micro motors thinner that a human hair. , ... Associate Professor James Friend and Senior Lecturer Leslie Yeo, ... from Monash,s Micro/Nanophysics Research Laboratory, then calculated how best ...
... Encorium Group, Inc. (Nasdaq: ENCO ) ... that provides design, development, and management capabilities for clinical ... leading pharmaceutical companies, today announced the signing of approximately ... new business contracts and repeat business to be conducted ...
... ("Sinobiopharma ", or "the Company") (OTC Bulletin Board: SNBP) ... to seven key patents from Company CEO Dr. Lequn ... significantly enhance Sinobiopharma,s ability to execute on its mission ... are for the following:, , ...
Cached Biology Technology:Pizza tossing art unlocks secrets of tiny motors 2Encorium Group Signs Approximately $2.0 Million of New Business Contracts 2Encorium Group Signs Approximately $2.0 Million of New Business Contracts 3Sinobiopharma Secures Rights to Seven Key Patents 2
(Date:12/17/2014)... DUBLIN , Dec. 16, 2014 Research ... announced the addition of the "Global Chemical ... http://photos.prnewswire.com/prnh/20130307/600769 ... is the increasing demand for medical sensors in ... patient data for quick and correct diagnosis during ...
(Date:12/11/2014)... , Dec. 09, 2014 Research and ... ( http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has ... in the APAC Region 2015-2019"  report to their ... in this market is advances in technology. With ... upgrade biometric solutions to the latest standard that ...
(Date:12/11/2014)... PAUL, Minn. , Dec. 10, 2014 /PRNewswire/ ... wireless physiologic monitoring, has released a new series ... needs of preclinical toxicology researchers. M series, part ... help toxicologists collect the best possible physiologic data ... Adding functional endpoints to toxicology studies ...
Breaking Biology News(10 mins):Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2New telemetry implants expected to change how large animal toxicology studies are conducted 2
... Vision, Inc.,(OTC Bulletin Board: INVI), a leading global ... has received an order for the,Company,s SharpEye(TM) system ... large,computer manufacturer. The SharpEye product provides analysis of ... quality in the manufacturing,process, and the system will ...
... Corporate Safe Specialists (CSS),announces an addition to its ... as National Account Manager., (Photo: http://www.newscom.com/cgi-bin/prnh/20080114/AQM106 ... Currey, Sales Manager of the Company, stated, "the ... accelerate the growth we,ve seen in,networked safe sales. ...
... STATION A specially developed carrot has been produced to ... A&M AgriLifes Vegetable and Fruit Improvement Center studied the calcium ... net increase in calcium absorption. The research, which was done ... carrot to the diet can help prevent such diseases as ...
Cached Biology News:Integral Vision, Inc. Announces SharpEye(TM) Order From New Customer 2Corporate Safe Specialists Announces Addition to Sales Team 2Got carrots? Vegetables may have bone to pick as calcium providers 2
Compound(s) tested through a broad panel of 38 ligand binding and enzyme assays targeting the Central Nervous System. Used to determine selectivity and potential GI liabilities of compounds....
... Versatile affinity matrix for the extraction ... proteins or other macromolecules, Applications: ,Reducing ... of the interaction of pure β-adrenergic ... Removing residual SDS in 6 M ...
... to the maintenance of appropriate levels ... important and diverse as those involved ... stress response, antigen presentation, modulation of ... cell cycle regulation, transcription, and signalling ...
Each Yeast-GFP clone represents an individual S. cerevisiae strain containing an open reading frame with a C-terminal Aequorea Victoria GFP (S65T) fusion tag....
Biology Products: